Drug ATX-304 Activates AMPK Pathway and Boosts Metabolism in First Human Trial
Cambrian Bio's ATX-304 reduced liver fat, visceral fat, and raised resting metabolic rate by 8% in a Phase 1b trial of adults with prediabetes.
Summary
A small but promising clinical trial has shown that ATX-304, a drug targeting the AMPK metabolic pathway, can produce measurable improvements in metabolic health in humans. AMPK is a cellular energy regulator that declines with age, contributing to weight gain, muscle loss, and conditions like fatty liver disease and diabetes. In an 8-week trial of 23 adults with obesity and prediabetes, participants taking ATX-304 showed reduced liver fat and visceral fat, improved triglycerides, higher adiponectin levels, and an 8% increase in resting metabolic rate. Side effects were mild and comparable to placebo, with no dangerous changes in heart rate or body temperature. This is one of the first times AMPK activation has been validated in human biology.
Detailed Summary
For decades, AMPK has been one of the most promising yet frustratingly elusive targets in aging biology. This cellular pathway acts as a master regulator of energy metabolism, helping cells respond efficiently to fuel availability. As we age, AMPK activity declines, contributing to reduced metabolic flexibility, muscle loss, weight gain, and increased risk of conditions like type 2 diabetes and fatty liver disease. Restoring AMPK function has long been theorized as a way to partially mimic the metabolic benefits of exercise — but translating that theory into human evidence has proven difficult. Until now.
Cambrian Bio presented Phase 1b results for ATX-304 at the American Diabetes Association's 86th Scientific Sessions. The randomized, placebo-controlled trial enrolled 23 adults with obesity and prediabetes, who received either ATX-304 or placebo for eight weeks. The primary goal was not dramatic weight loss but validation: could the drug actually activate the AMPK network in living humans the way lab models predicted?
The results were encouraging across multiple fronts. Participants on ATX-304 showed significant reductions in liver fat and visceral adipose tissue — the dangerous fat surrounding internal organs. Triglyceride levels improved, adiponectin (a hormone linked to healthy fat metabolism) increased substantially, and resting metabolic rate rose by 8%, meaning the body burned more energy at rest.
Critically, the drug achieved these effects without the safety red flags that have historically derailed metabolism-boosting therapies. No adverse changes were observed in body temperature or heart rate, and side effects were mild and comparable to placebo.
While these results are preliminary and the sample size is small, they represent a meaningful proof-of-concept moment for geroscience. If larger trials confirm these findings, ATX-304 could become a tool not just for metabolic disease, but for addressing the underlying biology of aging itself. Caution is warranted, but the signal is real.
Key Findings
- ATX-304 increased resting metabolic rate by 8%, meaning the body burns more calories at rest
- Liver fat and visceral fat were significantly reduced after just 8 weeks of treatment
- Adiponectin, a hormone tied to healthy fat metabolism, rose substantially in treated participants
- Triglyceride levels improved, supporting better cardiovascular and metabolic health
- No dangerous changes in heart rate or body temperature were observed, addressing key safety concerns
Methodology
This is a news report summarizing Phase 1b clinical trial data presented at the American Diabetes Association's 86th Scientific Sessions. The source, Longevity.Technology, is a reputable longevity-focused publication. The evidence is based on company-reported trial results; peer-reviewed publication of the full data has not yet been confirmed.
Study Limitations
The trial enrolled only 23 participants, making it underpowered to draw firm conclusions about efficacy or long-term safety. Results were presented at a conference and may not yet be peer-reviewed or published in full. As company-reported data, independent replication is essential before drawing broad conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.